BibTex format
@article{Gulati:2021:10.1016/j.kint.2021.08.025,
author = {Gulati, K and Edwards, H and Prendecki, M and Cairns, TD and Condon, M and Galliford, J and Griffith, M and Levy, JB and Tam, FWK and Tanna, A and Pusey, CD and McAdoo, SP},
doi = {10.1016/j.kint.2021.08.025},
journal = {Kidney International},
pages = {1316--1324},
title = {Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis},
url = {http://dx.doi.org/10.1016/j.kint.2021.08.025},
volume = {100},
year = {2021}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis can present with life-threatening lung-kidney syndromes. However, many controlled treatment trials excluded patients with diffuse alveolar hemorrhage or severely impaired glomerular filtration rates, and so the optimum treatment in these cases is unclear. In this retrospective cohort study, we report the outcomes of 64 patients with life-threatening disease treated with a combination regimen of rituximab, low-dose intravenous cyclophosphamide, oral glucocorticoids, and plasma exchange. At entry, the median estimated glomerular filtration rate was 9 mL/min, 47% of patients required dialysis, and 52% had diffuse alveolar hemorrhage. All patients received a minimum of seven plasma exchanges, and the median cumulative doses of rituximab, cyclophosphamide, and glucocorticoid were 2, 3, and 2.6 g, respectively, at six months. A total of 94% of patients had achieved disease remission (version 3 Birmingham Vasculitis Activity Score of 0) at this time point, and 67% of patients who required dialysis recovered independent kidney function. During long-term follow-up (median duration 46 months), overall patient survival was 85%, and 69% of patients remained free from end-stage kidney disease, which compares favorably to a historic cohort with severe disease treated with a conventional induction regimen. Combination treatment was associated with prolonged B cell depletion and low rates of relapse; 87% of patients were in continuous remission at month 36. The serious infection rate during total follow-up was 0.28 infections/patient/year, suggesting that combination treatment is not associated with an enduring risk of infection. Thus, we suggest that combination immunosuppressive therapy may permit glucocorticoid avoidance and provide rapid and prolonged disease control in patients with severe ANCA-associated vasculitis.
AU - Gulati,K
AU - Edwards,H
AU - Prendecki,M
AU - Cairns,TD
AU - Condon,M
AU - Galliford,J
AU - Griffith,M
AU - Levy,JB
AU - Tam,FWK
AU - Tanna,A
AU - Pusey,CD
AU - McAdoo,SP
DO - 10.1016/j.kint.2021.08.025
EP - 1324
PY - 2021///
SN - 0085-2538
SP - 1316
TI - Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis
T2 - Kidney International
UR - http://dx.doi.org/10.1016/j.kint.2021.08.025
UR - https://www.ncbi.nlm.nih.gov/pubmed/34560140
UR - https://doi.org/10.1080/07075332.2020.1763422
UR - http://hdl.handle.net/10044/1/91732
VL - 100
ER -
